MAIA Biotechnology (NYSEAMERICAN:MAIA – Get Free Report) is expected to be issuing its Q3 2026 resultson Friday, November 6th. Analysts expect MAIA Biotechnology to post earnings of ($0.13) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 6, 2026 at 9:30 AM ET.
MAIA Biotechnology (NYSEAMERICAN:MAIA – Get Free Report) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). On average, analysts expect MAIA Biotechnology to post ($0.54) EPS for the current fiscal year and ($0.48) EPS for the next fiscal year.
MAIA Biotechnology Price Performance
Shares of MAIA stock opened at $1.18 on Friday. The company has a market capitalization of $72.85 million, a P/E ratio of -1.90 and a beta of 0.27. The company’s 50-day simple moving average is $1.25 and its two-hundred day simple moving average is $1.46. MAIA Biotechnology has a one year low of $0.87 and a one year high of $3.19.
Insider Activity at MAIA Biotechnology
About MAIA Biotechnology
MAIA Biotechnology, Inc is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies. The company’s research is centered on treatments designed to address telomere biology, a process that plays an important role in the growth and survival of cancer cells.
MAIA’s lead investigational product is THIO, also known as 6-thio-2′-deoxyguanosine, a telomere-targeting agent intended to selectively affect cancer cells. The company has been evaluating THIO in combination with immune checkpoint inhibitors for patients with advanced or metastatic non-small cell lung cancer, including through its THIO-101 clinical program.
MAIA Biotechnology is headquartered in Chicago and is led by Chief Executive Officer Vlad Vitoc, M.D.
See Also
- Five stocks we like better than MAIA Biotechnology
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for MAIA Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MAIA Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
